Exubera's Benefits Outweigh Its Risks, Say FDA Advisers

Drug Industry Daily
KEYWORDS FDA / NDA
A A

Pfizer and sanofi-aventis’ potential breakthrough diabetes drug Exubera has received the green light from an FDA advisory panel, which voted 7-2 Sept. 8 to recommend approval for the inhaled insulin powder.

To View This Article:

Login

Subscribe To Drug Industry Daily